Navigation Links
Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy
Date:12/6/2008

s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2007.

Valeant Pharmaceuticals forward-looking statements

This press release contains forward-looking statements, including, but not limited to, statements regarding expectations or plans of development program for retigabine and the potential role retigabine could play in managing epilepsy and in treating other indications, and the commercial opportunity retigabine may present for Valeant. These statements are based upon the current expectations and beliefs of Valeant's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to the clinical development of retigabine, the fact that adverse events are not always immediately apparent even in well designed clinical trials, regulatory approval processes, the potential that competitors may bring to market drugs or treatments that are more effective of more commercially attractive than retigabine, and other risks and uncertainties discussed in the company's filings with the SEC. Valeant wishes to caution the reader that these factors are among the factors that could cause actual results to differ materially from the expectations described in the forward- looking statements. Valeant also cautions the reader that undue reliance should not be placed on any of the forward-looking statements, which speak only as of the date of this release. The company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this release or to reflect actual outcomes.

    Registered in England & Wales:
    No. 3888792

    Registered Office:
    980 Great West Road
    Brentfo
'/>"/>
SOURCE  GlaxoSmithKline; Valeant Pharmaceuticals International
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 

Related medicine technology :

1. Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
2. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
3. Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
4. Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
5. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
6. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
7. Successful Results for Mymetics Corporations Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
8. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
9. Hibernation-On-Demand Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss
10. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
11. New Study: Pine Bark Significantly Reduces Menstrual Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. (OTC ... medical device company that develops and sells high performance ... its rights offering.  In addition, the concurrent temporary reduction ... expired on May 17, 2013. Nephros estimates ... from the rights offering.   A portion of the proceeds ...
(Date:5/23/2013)... -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a ... intellectual property developed and owned by Hadassah University ... research center, today announced that its portfolio company, ... the Israeli Ministry of Industry and Commerce, Office ... development and advance clinical trials. Cell Cure,s development ...
(Date:5/23/2013)... , May 23, 2013  Texas, premier physician ... deliver doctors the survival tools they need to provide ... in today,s health care marketplace. "I am ... save local practices," said Stephen L. Brotherton ... (TMA). " Texas doctors are determined ...
Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4
... WASHINGTON, Oct. 16 The Post and Courier ... bus tour visited the Piggly Wiggly at 445 Meeting Street ... about programs that provide free or nearly free prescription medications. ... Partnership for Prescription Assistance , a nationwide effort sponsored ...
... Medco Health Solutions, Inc (NYSE: MHS ) today ... non-profit organization to support activities aimed at educating and ... safety issues; providing low income, disadvantaged and other distressed ... about medicine; and fostering and promoting opportunities for volunteerism ...
Cached Medicine Technology:The Medco Foundation Joins With the Entertainment Industry Foundation to 'Give Health a Hand' to Communities in Need 2The Medco Foundation Joins With the Entertainment Industry Foundation to 'Give Health a Hand' to Communities in Need 3
(Date:5/25/2013)... According to an article in the June 2013 issue ... million Americans tan indoors each year and an unknown number ... health risks. New research suggests that UV rays may ... brains of some tanners (Go to goo.gl/hdwnz). , “There ... say that I fully support this contention from a scientific ...
(Date:5/25/2013)... Dr. Leslie Gerstman announced today ... lift skin on the neck, on the brow and under ... Aesthetics. , Ultherapy is a non-surgical procedure for the face ... to lift the skin over time. The use of FDA-cleared ... and then treat the deepest support layers of the skin ...
(Date:5/25/2013)... A disorder of the nerves, Diabetic neuropathy ... to neuropathy expert doctor Helen C Lin, on Medscape ... disorder affects almost 50% of all Diabetic patients, making ... high blood sugar levels in the body are the ... usually tend to have abnormally high blood sugar levels. ...
(Date:5/25/2013)... The report “Global Food Encapsulation Market ... Ingredients, Shell Materials, Packaging, & Geography: Trends & ... market with analysis and forecasting of the global ... driving and restraining factors for the global food ... challenges. The market is segmented and revenue are ...
(Date:5/25/2013)... May 25, 2013 Absolute Surgical Specialists, serving ... of the NALA’s businesses throughout the country participating in Shop ... participate in the nationwide event as he understands what military ... in the Army. He said, “I wanted to give something ... serve, but I live here too.” , Shop Local for ...
Breaking Medicine News(10 mins):Health News:Sun Damage – Are UV Rays Addictive? 2Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2Health News:Diabetic Neuropathy treatment hits new grounds- Neuracel launches the complete natural treatment 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 3Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2
... cause damage to the brain of youngsters, says a ... misuse can do to them. // ,Thomas Heffernan, ... students for the research presented at the British Psychological ... of Daily Mail. ,Half the students ...
... research team from the New York University College of Dentistry ... oral decay evolved along with its human hosts. ... common ancestor who lived in Africa between 100,000 and 200,000 ... by Page Caufield, a professor of cariology and comprehensive care ...
... in EMBO says that the parasite that is responsible ... new pathway. Sleeping sickness is caused by Trypanosoma brucei ... ,Shulamit Michaeli and colleagues describe a pathway in T. ... this pathway shuts down the synthesis of a crucial ...
... the healthcare sector with a super-specialty hospital in Gurgaon,// on ... of Rs.2.1 billion ($45 million). ,Christened Artemis Health ... will open next month. "In the second phase, another 240 ... of AHS. ,"This is the first of similar ...
... governments to join the anti-tuberculosis global plan, which would ... disease has become extremely drug-resistant. ,Ban's message ... on Saturday. The World Health Organization (WHO) recently reported ... of tuberculosis, XDR-TB, which threatens to derail efforts to ...
... be hampered if they indulge in excessive drinking.// This ... a psychologist from Northumbria University. ,Alcohol and ... young age which could extend into adulthood. According to ... a very crucial stage. ,Dr. Thomas Heffernan ...
Cached Medicine News:Health News:Tooth Decay Bacteria Evolved Along With Man 2
The Acute Care myoglobin method is an in vitro diagnostic test for the measurement of myoglobin in heparinized whole blood /plasma. Myoglobin measurements can be used as an aid in diagnosing myocardi...
... The VITROS ECi brings true automation ... immunodiagnostic testing. Highly sensitive assays for ... and bone metabolism testing are currently ... development. The VITROS ECi can simultaneously ...
IRMA kit for detection of the cardiac marker Myoglobin...
... is intended for the quantitative determination of ... useful in the diagnosis and treatment of ... The BioCheck Prolactin Quantitative Test is based ... enzyme-linked immunosorbent assay. The assay system utilized ...
Medicine Products: